Promising Outlook for Cardiff Oncology’s Onvansertib Despite Phase II Trial Challenges

William Blair analyst Andy Hsieh has reiterated their bullish stance on CRDF stock, giving a Buy rating yesterday.

Andy Hsieh has given his Buy rating due to a combination of factors surrounding Cardiff Oncology’s recent updates on their Phase II trial of onvansertib for metastatic colorectal cancer. Despite a slight numerical miss in the objective response rate, the data indicates that onvansertib is active and enhances the standard of care, which counters negative perceptions about the stock.
The analysis suggests that even a modest improvement in response rates could translate into significant benefits in progression-free survival, as seen in similar studies. Cardiff’s management plans to engage with the FDA regarding the Phase III trial design, potentially including an accelerated approval pathway, which underscores the promising outlook for onvansertib and supports continued investment.